Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive OfficerCapital to enable Phase 2 trials for Metabolic Neuromodulation Therapy, an important new treatment for Type 2 diabetes. MINNEAPOLIS, January 8, 2018-- Metavention, Inc., today announced the completion of $65 million in Series C financing. The financing was led by New Enterprise Associates (NEA) and included participation from new investors Sanderling Ventures, RK Mellon and Horowitz Group, plus existing investors Versant Ventures and a corporate investor.